18F-FDG PET/CT分期改变浸润性膀胱癌治疗推荐
该回顾性分析纳入2011至2020年711例浸润性尿路上皮膀胱癌患者,在常规增强CT分期后行FDG-PET/CT。FDG-PET/CT使26%患者临床分期改变,18%患者治疗策略改变,9.1%由潜在治愈转为姑息治疗。
要点
- FDG-PET/CT使26%的肌层浸润性膀胱癌患者临床分期发生改变。
- 18%患者基于影像的治疗推荐发生改变,9.1%转为姑息治疗。
- FDG-PET/CT可检出第二原发肿瘤,但8.1%存在假阳性次要发现。
核心结论
- FDG-PET/CT提供重要的增量分期信息,可能影响18%的肌层浸润性膀胱癌患者的临床管理,但也会导致假阳性结果。
研究设计与样本
- 回顾性分析2011至2020年单中心711例连续浸润性尿路上皮膀胱癌患者,均行增强CT(胸部及腹部)和FDG-PET/CT分期。
主要发现
- FDG-PET/CT后临床分期改变184/711(26%)例。
- 基于影像的治疗策略改变127/711(18%)例。
- 65/711(9.1%)例因FDG-PET/CT检出远处转移由潜在治愈治疗转为姑息治疗。
临床怎么用
- 建议将FDG-PET/CT作为膀胱癌分期的一部分,以优化治疗决策。
局限性
- 回顾性分析,单中心数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the high risk of systemic relapse following initial therapy for muscle-invasive bladder cancer (MIBC), improved pretreatment staging is needed. We evaluated the incremental value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) after standard conventional staging, in the largest cohort of MIBC patients to date. This is a retrospective analysis of 711 consecutive patients with invasive urothelial bladder cancer who underwent staging contrast-enhanced CT (chest and abdomen) and FDG-PET/CT in a tertiary referral center between 2011 and 2020. We recorded the clinical stage before and after FDG-PET/CT and treatment recommendation based on the stage before and after FDG-PET/CT. Clinical stage changed after FDG-PET/CT in 184/711 (26%) patients. Consequently, the recommended treatment strategy based on imaging changed in 127/711 (18%) patients. In 65/711 (9.1%) patients, potential curative treatment changed to palliative treatment because of the detection of distant metastases by FDG-PET/CT. Fifty (7.0%) patients were selected for neoadjuvant/induction chemotherapy based on FDG-PET/CT. Moreover, FDG-PET/CT detected lesions suspicious for second primary tumors in 15%; a second primary malignancy was confirmed in 28/711 (3.9%), leading to treatment change in ten (1.4%) patients. Contrarily 57/711 (8.1%) had false positive secondary findings. In conclusion, FDG-PET/CT provides important incremental staging information, which potentially influences clinical management in 18% of MIBC patients, but leads to false positive results as well. PATIENT SUMMARY: In this report, we investigated the impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scanning on treatment of bladder cancer patients. We found that FDG-PET/CT potentially influences the treatment of almost one-fifth of patients. We therefore suggest performing FDG-PET/CT as part of bladder cancer staging.
引用
- Voskuilen CS, van Gennep EJ, Einerhand SMH, et al. Staging 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Changes Treatment Recommendation in Invasive Bladder Cancer. Eur Urol Oncol. 2021. PMID: 33583752. doi:10.1016/j.euo.2021.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。